## Table S1. Amino acid sequence substitutions in hemagglutinin (HA) and neuraminidase (NA) of MDCK-passaged assay and challenge viruses with affected antigenic sites indicated in parentheses relative to comparator strains

## A. Comparator strains: posted references strains recommended by the WHO<sup>a</sup> for use in the 2008-09 trivalent influenza vaccine

Viruses used in antibody assays	Passage <sup>b</sup> Number	Haemagglutination Inhibition Assay		Microneutralization Assay	
		HA	NA	HA	NA
A/Brisbane/59/2007(H1N1)-like (Seasonal H1N1)	2	Asp/lle186Asn (Sb)c	Noned	Asp/Ile186Asn (Sb) Asp438Asne	Noned
A/Brisbane/10/2007(H3N2)-like <sup>f</sup> (Seasonal H3N2)	3	Asn96Ser (D) Leu194Pro (B)	None	Asn96Ser (D) Leu194Pro (B)	None
B/Florida/4/2006-like (Influenza B)	2	None	Noneh	Mix Gly414Aspi	Noneh
A/California/7/2009-like <sup>j</sup> A(H1N1)pdm09 (WHO reference)	3	Ser183Pro	None	Ser183Pro	None
A/Quebec/144147/2009(H1N1) <sup>k</sup> A(H1N1)pdm09 (challenge virus)	3	Pro83Ser Ser203Thr (Ca1) Ile321Val	Val106lle Asn248Asp	Pro83Ser Ser203Thr (Ca1) Ile321Val	Val106lle Asn248As

B. Comparator strains: egg-passaged reassortant influenza A/H1N1<sup>1</sup> and A/H3N2<sup>m</sup> vaccine strains actually used by manufacturers in the 2008-09 trivalent influenza vaccine

Viruses used in antibody assays	Passage <sup>b</sup> Number	Haemagglutination Inhibition Assay		Microneutralization Assay	
		HA	NA	HA	NA
A/Brisbane/59/2007(H1N1)-like (Seasonal H1N1)	2	None	Noned	Asp438Asne	Noned
A/Brisbane/10/2007(H3N2)-like <sup>f</sup> (Seasonal H3N2)	3	Asn96Ser (D) Ser138Ala (A) <sup>n</sup> Gly142Arg (A) <sup>n</sup>	Thr26llen Ile32Thrn His150Argn Ile267Thrn Ile312Thrn	Asn96Ser (D) Ser138Ala (A) <sup>n</sup> Gly142Arg (A) <sup>n</sup>	Thr26llen Ile32Thrn His150Argn Ile267Thrn Ile312Thrn

Note: Amino acid numbering begins at first neuraminidase methionine for NA and after removal of the signal peptide for HA (residues 1-16 for H3, 1-17 for H1 and 1-15 for influenza B).

- a. GenBank/GISAID Accession Numbers: CY035022, CY035024, CY030230, EPI162332, CY033876, CY033878, FJ981613, FJ984386
- b. Passaged in Madin Darby canine kidney (MDCK) cells
- c. GenBank Accession Number KF009550
- d. GenBank Accession Number CY065749
- e. GenBank Accession Number CY065747
- f. GenBank Accession Numbers CY065751 (HA) and CY065752 (NA)
- g. GenBank Accession Number KF009552
- h. GenBank Accession Number CY073896
- i. GenBank Accession Number CY073895
- j. GenBank Accession Numbers KF009554-KF009555
- k. GenBank Accession Numbers FN434457-FN434464
- 1. A/Brisbane/59/2007 (H1N1) IVR-148
- m. A/Uruguay/716/2007 (H3N2) X-175C
- n. Differences due to manufacturer vaccine virus strain selection rather than passage of WHO reference virus used in antibody assays.

**Summary:** For seasonal H1N1 there was 100% HA and NA identity between assay and vaccine (IVR-148) viruses. For A(H1N1)pdm09 there was a single AA HA antigenic site and 2AA NA difference between assay and challenge viruses. For H3N2 the MDCK-passaged virus showed 2AA HA antigenic site and no NA differences from the WHO-recommended reference virus but 3AA HA antigenic site differences from the X-175C vaccine component actually used by manufacturers. However, the X-175C vaccine component itself differed from the WHO-recommended reference by 3AA in the HA and 5AA in the NA. See **Table S2** for percent pairwise identity calculations for HA1 and antigenic sites.

Version: December 21, 2013